Trial Profile
Phase I trial of SYN 005 for the treatment of pertussis
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 26 Mar 2015
Price :
$35
*
At a glance
- Drugs SYN 005 (Primary)
- Indications Pertussis
- Focus Adverse reactions
- Sponsors Theriva Biologics
- 16 Mar 2015 According to Synthetic Biologics media release, orphan drug designation has been granted to SYN 005, by the US FDA
- 08 Sep 2014 New trial record